Inflammatory Myositis (IM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Inflammatory Myositis (IM) Market Outlook

Thelansis’s “Inflammatory Myositis (IM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inflammatory Myositis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Inflammatory Myositis (IM) Overview

Inflammatory myopathies represent a spectrum of muscular disorders characterized by inflammation, stemming from autoimmune dysregulation wherein the body's immune system erroneously targets its own muscle tissues. Predominant among these conditions are dermatomyositis and polymyositis, though the taxonomy of inflammatory myopathies remains dynamic, with ongoing identification of novel subtypes. Dermatomyositis primarily manifests as muscle weakness, notably affecting the musculature of the cervical, scapular, and pelvic regions, and also presents with cutaneous manifestations. Respiratory compromise may also ensue in some instances. While inflammatory myopathies can affect individuals across age groups and ethnicities, their incidence is relatively infrequent, with a predilection for onset in childhood (typically between ages 5 and 10) and adulthood (typically between ages 40 and 50) and a higher occurrence in females compared to males. The clinical evaluation of suspected inflammatory myopathies commences with a thorough assessment of muscle strength, supplemented by ancillary investigations conducted by a rheumatologist. These investigations may include serological assays to quantify muscle enzymes and myositis-specific antibodies, electromyography to assess muscular electrical activity, and magnetic resonance imaging to visualize structural muscle abnormalities. Initial therapeutic intervention typically involves administration of oral corticosteroids, notably prednisone, often at elevated dosages. Observably, normalization of muscle enzyme levels is commonly achieved within 4 to 6 weeks post-commencement of treatment, with concomitant restoration of muscular strength typically occurring within 2 to 3 months. However, individuals with severe presentations may necessitate adjunctive therapies such as intravenous immunoglobulin, cyclosporine, tacrolimus, mycophenolate mofetil, or rituximab.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: